ArticleDiscover oncology2025
Anatomic subtype-specific causal effects of endometriosis on ovarian cancer: a two-sample Mendelian randomization study.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Differential risk of adverse drug reactions with baricitinib across age groups: integrating real-world pharmacovigilance and genetic causal inference.Therapeutic advances in drug safety · 2025Article
- The Association Between Endometriosis and an Increased Risk of Epithelial Ovarian Cancer and Cardiovascular Disease: Perspective on a Patient-Centered Approach to Endometriosis, a Heterogeneous Disease.Reproductive medicine and biologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
While epidemiological studies have associated endometriosis with ovarian cancer risk, the causal relationships across anatomic subtypes and histotypes remain undefined. Using two-sample Mendelian randomization with 84 genetic instruments (F-statistic = 30.01-228.09), we analyzed genome-wide data from 20,190 endometriosis cases and 25,509 ovarian cancer patients. Genetically proxied endometriosis significantly increased risks of overall ovarian cancer [OR = 1.18, 95% confidence interval (95%CI): 1.10-1.28), high-grade serous (OR:1.12, 95% CI 1.01-1.23), clear cell (OR:1.87, 95% CI 1.44-2.43), and endometrioid carcinomas (OR:1.48, 95% CI 1.30-1.69)]. Anatomic subtype analyses revealed differential effects. Pelvic peritoneal lesions showed the highest risk for clear cell carcinoma (OR = 1.81, 95% CI 1.52-2.16). Deep endometriosis broadly impacted high-grade serous (OR = 1.10, 95% CI 1.04-1.17) and endometrioid carcinomas (OR = 1.25, 95% CI 1.13-1.40). Ovarian endometriosis specifically elevated clear cell (OR = 1.65, 95% CI 1.46-1.86) and endometrioid risks (OR = 1.48, 95% CI 1.30-1.69;). Rectovaginal lesions selectively increased endometrioid carcinoma risk (OR = 1.25, 95% CI 1.04-1.51). No associations were emerged between any type of endometriosis for low-grade serous or invasive mucinous ovarian. Significant heterogeneity was detected in ovarian endometriosis-mucinous cancer associations persisting after MR-PRESSO outlier correction, while other associations retained consistent effect sizes post-adjustment. Funnel plot symmetry, leave-one-out stability, and MR-Egger intercept collectively confirmed result robustness without directional pleiotropy. This study provides novel evidence that endometriosis causally increases risk of specific ovarian cancer histotypes, particularly demonstrating that anatomic subtypes represent distinct etiological entities with differential oncogenic potential, where pelvic peritoneal lesions emerge as a previously underappreciated high-risk subtype for clear cell carcinoma development, thereby offering critical insights for refining risk stratification protocols and guiding targeted surveillance strategies in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.